Corroborating our findings, biallelic deletions and inactivating mutations of the Traf3 gene have been identified in human patients with a variety of B cell neoplasms, including multiple myeloma (MM), splenic marginal zone lymphoma (MZL), B cell chronic lymphocytic leukemia (B-CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), and Hodgkin lymphoma [10–17]. This evidence concerns the gene TRAF3 and Waldenstrom macroglobulinemia.